{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:40:57Z","timestamp":1784259657536,"version":"3.55.0"},"reference-count":23,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,8,14]]},"DOI":"10.18632\/oncotarget.4378","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T04:50:54Z","timestamp":1442292654000},"page":"19819-19825","source":"Crossref","is-referenced-by-count":80,"title":["Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1"],"prefix":"10.18632","volume":"6","author":[{"given":"Zoran","family":"Gatalica","sequence":"first","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurija","family":"Bilalovic","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Palazzo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Bender","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Swensen","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri Z.","family":"Millis","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semir","family":"Vranic","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"Department of Oncology, Virginia G. Piper Cancer Center at Scottsdale Healthcare\/TGen, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Arceci","sequence":"additional","affiliation":[{"name":"Department of Child Health, University of Arizona College of Medicine, Phoenix, Ronald Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.14694\/EdBook_AM.2014.34.e441","article-title":"Biological and therapeutic implication of the BRAF pathway in histiocytic disorders","author":"Arceci","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Meyerson","year":"2010","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.18632\/oncotarget.2061","article-title":"Potential clinical implications of BRAF mutations in histiocytic proliferations","volume":"5","author":"M\u00f6ller","year":"2014","journal-title":"Oncotarget"},{"key":"4","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Rose","year":"2012","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2159-8290.CD-14-0742","article-title":"Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders","volume":"5","author":"Lacouture","year":"2015","journal-title":"Cancer Discov"},{"key":"6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease","volume":"33","author":"Besnard","year":"2015","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Amoura","year":"2013","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"9","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Anders","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Antonia","year":"2012","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Sharpe","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"12","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Hamid","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"13","doi-asserted-by":"publisher","first-page":"pii","DOI":"10.1053\/j.semdp.2015.02.010","article-title":"BRAF V600E mutation-specific antibody: A review","author":"Barletta","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.humpath.2013.10.026","article-title":"Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization","volume":"45","author":"Pai","year":"2014","journal-title":"Hum Pathol"},{"key":"15","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Hu","year":"2014","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood-2013-02-482984","article-title":"Detection of an NRAS mutation in Erdheim-Chester disease","volume":"122","author":"Rosenblum","year":"2013","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"Le Gall","year":"2014","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/his.12416","article-title":"Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms","volume":"65","author":"Kim","year":"2014","journal-title":"Histopathology"},{"key":"19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2006.03.028","article-title":"The PTEN and INK4A\/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans","volume":"9","author":"Cavenee","year":"2006","journal-title":"Cancer Cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.18632\/oncotarget.2574","article-title":"Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases","volume":"5","author":"Von Hoff","year":"2014","journal-title":"Oncotarget"},{"key":"21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ligon","year":"2015","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Rodig","year":"2013","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000272951","article-title":"Distribution of PD-1+ lymphocytes in reactive lymphadenopathies","volume":"77","author":"Tzankov","year":"2010","journal-title":"Pathobiology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:20:50Z","timestamp":1599556850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2015,8,14]]}},"alternative-id":["4378","26110571"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4378","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]}}}